New Gastric Cancer Drug Could Improve Survival Odds
A new targeted therapy extended median survival for patients with advanced stomach cancer in a recent Phase III trial.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe current pharmaceutical investments in targeted cancer therapies are successfully extending patient survival?
AstraZeneca's investigational drug sonesitatug vedotin showed significant survival benefits for patients with advanced gastric and gastroesophageal cancers in the Phase III CLARITY-Gastric01 trial. The findings, which were recently presented at the ESMO congress, highlight a potential new treatment pathway for patients in later lines of therapy.
Why it matters
This development represents a potential shift in care for individuals with advanced gastrointestinal cancers who have limited options after failing initial standard treatments. By targeting CLDN18.2 protein expression, the therapy may offer improved survival outcomes for patients whose tumors express this specific marker.
The CLARITY-Gastric01 trial enrolled 594 patients to evaluate the efficacy of sonesitatug vedotin compared to standard therapies. While the study met its primary endpoint for overall survival in third-line and later settings, it failed to meet the endpoint for progression-free survival.
The players
AstraZeneca
A global pharmaceutical company focused on the development of oncology, cardiovascular, and respiratory therapies.
KYM Biosciences
A biotechnology company that develops targeted cancer therapies and licensed this drug candidate.
The details
Sonesitatug vedotin is a targeted treatment designed to identify and act on tumor cells expressing the CLDN18.2 protein. The trial showed that patients with higher tumor CLDN18.2 expression saw the most significant benefits, including a 41% lower risk of death for those with 75% or higher expression. Researchers evaluated these outcomes against the physician-selected standard of care to measure the drug's impact on overall survival in patients with previously treated cancers.
Timeline
AstraZeneca licensed the drug from KYM Biosciences in 2023.
CLARITY-Gastric01 trial results were toplined in July 2026.
Detailed Phase III results were presented on October 25, 2026, at the ESMO congress.
Health Landscape
This study underscores the growing clinical focus on targeting specific protein biomarkers like CLDN18.2 to treat advanced gastric cancers. It sits alongside the ongoing CLARITY-Gastric02 trial, which is currently evaluating the drug's effectiveness in earlier, first-line treatment settings.
Patients with advanced gastric or gastroesophageal cancer may want to consult their oncologist about the significance of CLDN18.2 tumor testing. These results demonstrate how biomarker-driven therapy is evolving, though the treatment is currently investigational and not yet a clinical standard.
The takeaway
Targeted therapies are increasingly offering survival advantages for patients with refractory gastric cancers by focusing on specific tumor proteins. Patients should discuss the role of biomarker testing for CLDN18.2 with their care team when reviewing treatment options for advanced disease.
Further reading
For more information on the latest developments in oncology, visit the Cancer section.
Live Poll
Do you believe current pharmaceutical investments in targeted cancer therapies are successfully extending patient survival?
